Journal article
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
Blood, Vol.98(9), pp.2865-2868
11/01/2001
DOI: 10.1182/blood.V98.9.2865
PMID: 11675364
Abstract
Abstract Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma.
Details
- Title: Subtitle
- Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
- Creators
- Richard L Piekarz - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDRob Robey - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDVictor Sandor - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDSusan Bakke - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDWyndham H Wilson - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDLaila Dahmoush - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDDouglas M Kingma - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDMaria L Turner - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDRosemary Altemus - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MDSusan E Bates - From the Medicine Branch, the Laboratory of Pathology, the Dermatology Branch, and the Radiation Oncology Branch of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.98(9), pp.2865-2868
- DOI
- 10.1182/blood.V98.9.2865
- PMID
- 11675364
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/01/2001
- Academic Unit
- Pathology; Urology
- Record Identifier
- 9984047653802771
Metrics
12 Record Views